Aurora Cannabis Inc (ACB) is a well-known company in the global cannabis industry, operating across 25 countries. Headquartered in Edmonton, Alberta, Canada, the company is publicly traded on the Toronto Stock Exchange and the New York Stock Exchange since October 2018. ACB is committed to setting the highest standards for product quality, client services, and innovative developments within this burgeoning industry.
Aurora specializes in the production and distribution of medical cannabis, with a broad and extensive product portfolio that includes dried cannabis, cannabis oil, softgels, oral dissolvable wafers, vaporizer, and topicals. The company’s products are designed to serve an array of cannabis markets, including medical patients, adult-use consumers, and wellness-focused consumers.
ACB's medical cannabis business is its core strength, recognized by physician and patient communities worldwide. It has a robust medical research strategy, partnering with globally acclaimed research-focused organizations, resulting in several initiated clinical trials and case studies with the goal of advancing knowledge of cannabinoids as medically therapeutic solutions.
Aurora is serving the consumer market under numerous well-reputed brands that cater to an array of consumer preferences. Since the legalization of recreational cannabis in Canada in October 2018, Aurora has proven itself as a dominant player in this market segment as well.
Aside from its primary business activities, ACB is also committed to sustainability and community engagement. The company operates with an environmentally friendly approach, using purpose-built indoor cannabis facilities with advanced climate control systems that reduce waste and energy usage. Aurora frequently gives back to the communities in which it operates, notably through job creation, investing in local infrastructure, and supporting local charities and non-profit organizations.
However, the rapid growth and regulatory changes in the cannabis industry have given rise to challenges for most cannabis companies including ACB. Slower than expected retail rollouts and over-supply situations have affected the sales and profitability of the industry, leading to a downturn in Aurora’s stock prices.
Despite these challenges, Aurora Cannabis Inc continues to shape the future of cannabis as a leading player in this growing sector - building high-quality cannabis products, investing in research and development, and generating significant employment to create a robust and sustainable industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aurora Cannabis Inc. (ACB) shares dropped 1.17% on Wednesday, closing at $5.05. This decline occurred despite a positive trading session for the broader market, with both the NASDAQ Composite Index and the Dow Jones Industrial Average seeing gains. This marks the third consecutive day of losses for Aurora Cannabis stock.
Global law firm Hogan Lovells Cadwalader advised Organigram Global Inc. on its proposed CAD561 million acquisition of Aurora Cannabis Inc. This strategic move aims to create a global cannabis leader with significant presence across Canada, Europe, and Australia. The transaction, which brings together strengths in recreational and medical cannabis markets, is pending shareholder, court, and regulatory approvals and is expected to close in January 2027.
Curaleaf Holdings, Inc. announced it has received all necessary competition law clearances in Germany and Canada for its proposed acquisition of Aurora Cannabis Inc. These clearances eliminate regulatory hurdles in the only two jurisdictions where such approvals were required, strengthening Curaleaf's offer which is set to expire on December 4, 2026. The company believes this provides greater certainty and a faster path to closing for Aurora shareholders compared to competing proposals.
This article analyzes Aurora Cannabis Inc. (ACB) through a rotational strategy lens, providing insights for different trading horizons. It highlights a strong near and mid-term sentiment but a weak long-term outlook for the stock. The report details three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop loss levels derived from AI models.
Aurora Cannabis (TSE:ACB) has filed its unaudited interim financial statements and management's discussion for the three and six months ended September 30, 2026. The statements show an increase in cash and cash equivalents, restricted cash, and short-term investments, as well as a rise in inventory and property, plant, and equipment. TipRanks' AI Analyst, Spark, rates ACB as Neutral due to weak financial performance despite a strong balance sheet.
Organigram Global Inc. has reached a friendly agreement to acquire Aurora Cannabis Inc. for $561 million, following Aurora's rejection of a hostile takeover bid from Curaleaf Holdings Inc. The deal offers Aurora shareholders cash or Organigram shares and has received unanimous board support from both companies. Curaleaf, whose enhanced offer for Aurora remains outstanding, believes its proposal represents superior value.
Curaleaf has issued a statement reaffirming its October 6, 2026 bid to acquire Aurora Cannabis remains open, despite Aurora's announcement of an alternative transaction with Organigram. Curaleaf contends its offer provides superior value, certainty, and speed to close, while criticizing Aurora's board for refusing direct engagement. The company also highlights that key terms of the Organigram deal, including any break fee and potential dilution, have not yet been disclosed to shareholders.
Aurora Cannabis Inc. (NASDAQ: ACB) shares surged after the company agreed to be acquired by Organigram Global for C$7.80 per share, an offer that significantly tops a previous hostile bid from Curaleaf. The deal values Aurora at approximately C$561 million and provides shareholders with options for cash, Organigram stock, or a combination. The combined entity expects over C$50 million in synergies and leadership positions in major cannabis markets.